At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
TAK-906 Maleate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Sequence, Open-Label, 2-Period, Crossover Trial to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Single-Dose Pharmacokinetics of Oral TAK-906 in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-906 Maleate and Itraconazole for Healthy Participants. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effect of the potent cytochrome P-450 (CYP) 3A4 inhibitor (itraconazole) on the single-dose PK of oral TAK-906 maleate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJun 2017
Primary CompletionJul 2017
Study CompletionJul 2017
TodayJul 2026
First PostedMay 19, 2017
Enrollment StartJun 5, 2017
Primary CompletionJul 2, 2017
Study CompletionJul 10, 2017
TodayJul 2, 2026
Enrollment to primary: 27 daysPosted 9.1 years ago
Interventions
TAK-906 Maleatedrug
TAK-906 capsule
Itraconazoledrug
Itraconazole solution